That sounds a reasonable interpretation to me. The very small sample size of 10 for June conclusion worried me but I guess if the adverse effects of AZD-4320 had been 100% pervasive, none of which were seen in the 10 participants in the AZD-0466 version, then that's safety proven and onto an enhanced Phase I efficacy trial, going worldwide this time and with some extra indications thrown in! Do we now expect to see a new trial defined with the extra cohort numbers, new endpoints/success criteria and completion dates?
SPL Price at posting:
$2.00 Sentiment: Buy Disclosure: Held
